Overland Forms $50 Million China JV to Develop ADCs with Swiss Biopharma
publication date: Dec 14, 2020
Overland Pharmaceuticals, a China in-licensing newco backed by Hillhouse Capital, will form a JV with Switzerland's ADC Therapeutics to develop four ADC Therapeutics antibody drug conjugate drugs in China and Singapore. Overland will own 51% of the JV, which will be called Overland ADCT Biopharma, in exchange for a $50 million investment. A Shanghai, Beijing, Boston biopharma, Overland broke out of stealth mode last week with a plan to develop advanced technologies drugs in China, including ADCs, cell therapies and RNAi candidates. More details....
Stock Symbol: (NYSE: ADCT)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.